

SCHEDULE 1

Regulation 3

CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS  
OF REGULATIONS 14, 15, 16, 18, 19, 20, 23, 26 AND 27

1. The following substances and products, namely -

(a) Bufotenine

Cannabinol  
Cannabinol derivatives not being dronabinol or its stereoisomers  
Cannabis and cannabis resin  
Cathinone  
Coca leaf  
Concentrate of poppy-straw  
Eticyclidine  
Etryptamine  
Lysergamide  
Lysergide and other *N*-alkyl derivatives of lysergamide  
Mescaline  
Methcathinone  
Psilocin  
Raw opium  
Rolicyclidine  
Tenocyclidine  
4-Bromo-2,5-dimethoxy- $\alpha$ -methylphenethylamine  
*N,N*-Diethyltryptamine  
*N,N*-Dimethyltryptamine  
2,5-Dimethoxy- $\alpha$ ,4-dimethylphenethylamine  
*N*-Hydroxy-tenamphetamine  
4-Methyl-aminorex

(b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

(c) the following phenethylamine derivatives, namely—

Allyl( $\alpha$ -methyl-3,4-methylenedioxyphenethyl)amine  
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol  
2-Amino-1-(3,4-dimethoxyphenyl)ethanol  
Benzyl( $\alpha$ -methyl-3,4-methylenedioxyphenethyl)amine  
4-Bromo- $\beta$ ,2,5-trimethoxyphenethylamine  
*N*-(4-*sec*-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine  
Cyclopropylmethyl( $\alpha$ -methyl-3,4-methylenedioxyphenethyl)amine  
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

*Status: This is the original version (as it was originally made).*

2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine  
 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine  
 2-(1,4-Dimethoxy-2-naphthyl)ethylamine  
 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine  
*N*-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine  
 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine  
 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine  
 $\alpha$ ,  $\alpha$ -Dimethyl-3,4-methylenedioxyphenethylamine  
 $\alpha$ , $\alpha$ -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine  
 Dimethyl( $\alpha$ -methyl-3,4-methylenedioxyphenethyl)amine  
*N*-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine  
 4-Iodo-2,5-dimethoxy- $\alpha$ -methylphenethyl(dimethyl)amine  
 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine  
 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine  
 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine  
 2-Methoxyethyl( $\alpha$ -methyl-3,4-methylenedioxyphenethyl)amine  
 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine  
 $\beta$ -Methoxy-3,4-methylenedioxyphenethylamine  
 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine  
 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine  
 2-( $\alpha$ -Methyl-3,4-methylenedioxyphenethylamino)ethanol  
 $\alpha$ -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine  
*N*-Methyl-*N*-( $\alpha$ -methyl-3,4-methylenedioxyphenethyl)hydroxylamine  
*O*-Methyl-*N*-( $\alpha$ -methyl-3,4-methylenedioxyphenethyl)hydroxylamine  
 $\alpha$ -Methyl-4-(methylthio)phenethylamine  
 $\beta$ ,3,4,5-Tetramethoxyphenethylamine  
 $\beta$ ,2,5-Trimethoxy-4-methylphenethylamine

- (d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an *N*-alkylphenethylamine,  $\alpha$ -methylphenethylamine, an *N*-alkyl- $\alpha$ -methylphenethylamine,  $\alpha$ -ethylphenethylamine, or an *N*-alkyl- $\alpha$ -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents;
- (e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
  - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
  - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;

- (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups;
  - (v) by substitution at the 4-position of the piperidine ring with any alkoxy carbonyl or alkoxyalkyl or acyloxy group;
  - (vi) by replacement of the *N*-propionyl group by another acyl group;
- (f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
  - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
  - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
  - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy carbonyl or any alkoxyalkyl or acyloxy group;
  - (v) by formation of an *N*-oxide or of a quaternary base.
2. Any stereoisomeric form of a substance specified in paragraph 1.
  3. Any ester or ether of a substance specified in paragraph 1 or 2.
  4. Any salt of a substance specified in any of paragraphs 1 to 3.
  5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.